Have a feature idea you'd love to see implemented?
Let us know!
MRNA Moderna Inc
Price (delayed)
$38.25
Market cap
$14.72B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.81
Enterprise value
$14.38B
Moderna is an American, Cambridge, Massachusetts-based biotechnology company focused on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA . The Moderna technology platform is to insert
Highlights
MRNA's gross profit has soared by 105% from the previous quarter
The gross margin has soared by 104% from the previous quarter and by 79% YoY
MRNA's revenue is down by 44% year-on-year
The equity is down by 11% YoY
Key stats
What are the main financial stats of MRNA
Market
Valuations
Earnings
Shares outstanding
384.82M
Market cap
$14.72B
Enterprise value
$14.38B
Price to book (P/B)
1.23
Price to sales (P/S)
2.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.83
Revenue
$5.08B
EBIT
-$2.35B
EBITDA
-$2.02B
Free cash flow
-$3.96B
Per share
Balance sheet
Liquidity
EPS
-$5.81
Free cash flow per share
-$10.28
Book value per share
$31.03
Revenue per share
$13.2
TBVPS
$41.05
Total assets
$15.8B
Total liabilities
$3.88B
Debt
$1.3B
Equity
$11.93B
Working capital
$7.47B
Debt to equity
0.11
Current ratio
4.39
Quick ratio
3.83
Net debt/EBITDA
0.17
Margins
Efficiency
Dividend
EBITDA margin
-39.8%
Gross margin
67.4%
Net margin
-43.8%
Operating margin
-53%
Return on assets
-13.3%
Return on equity
-17.7%
Return on invested capital
-17.9%
Return on capital employed
-17.3%
Return on sales
-46.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MRNA stock price
How has the Moderna stock price performed over time
Intraday
3.55%
1 week
-3.82%
1 month
-28.9%
1 year
-50.41%
YTD
-61.54%
QTD
-42.77%
Financial performance
How have Moderna's revenue and profit performed over time
Revenue
$5.08B
Gross profit
$3.43B
Operating income
-$2.69B
Net income
-$2.22B
Gross margin
67.4%
Net margin
-43.8%
MRNA's gross profit has soared by 105% from the previous quarter
The gross margin has soared by 104% from the previous quarter and by 79% YoY
Moderna's operating margin has shrunk by 82% YoY but it has increased by 42% QoQ
The net margin has surged by 62% since the previous quarter but it has declined by 15% year-on-year
Growth
What is Moderna's growth rate over time
Valuation
What is Moderna stock price valuation
P/E
N/A
P/B
1.23
P/S
2.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.83
The company's EPS has surged by 62% QoQ and by 36% YoY
MRNA's P/B is 81% below its 5-year quarterly average of 6.6 and 59% below its last 4 quarters average of 3.0
The equity is down by 11% YoY
The stock's P/S is 93% below its 5-year quarterly average of 40.4 and 58% below its last 4 quarters average of 6.9
MRNA's revenue is down by 44% year-on-year
Efficiency
How efficient is Moderna business performance
The company's return on sales has shrunk by 79% YoY but it rose by 46% QoQ
MRNA's return on equity has surged by 61% since the previous quarter and by 13% year-on-year
Moderna's ROA has soared by 60% from the previous quarter and by 13% YoY
The ROIC has grown by 46% from the previous quarter but it has contracted by 25% YoY
Dividends
What is MRNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MRNA.
Financial health
How did Moderna financials performed over time
The quick ratio has soared by 78% YoY and by 4.6% from the previous quarter
The current ratio has surged by 78% year-on-year and by 7% since the previous quarter
The debt is 89% smaller than the equity
The company's debt to equity rose by 22% YoY
The equity is down by 11% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.